10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
10x Genomics, Inc.NASDAQ: TXG
Net Debt · Q3 FY2026 · quarter ended Sep 2026
Net debt remains negative
Q3 FY2026 net debt was -$450.4M, compared with -$269.08M a year earlier.
Context
- Net debt amounted to 42.4% of total assets at the end of Q3 FY2026, up 16.2 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -67.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (316.23M) USD
- Year-over-year change
- -21.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (316.23M) | -21.0% |
| FY2024 | 2024-12-31 | (261.45M) | +0.9% |
| FY2023 | 2023-12-31 | (263.91M) | -111.9% |
| FY2022 | 2022-12-31 | (124.57M) | +75.4% |
| FY2021 | 2021-12-31 | (505.47M) | — |
Net Debt vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's Sep 2026 net debt of -$450.4M is the lowest of the 9 companies compared; the peer median is $780.91M.
- Its year-over-year change of -67.4% is the 6th highest of 9, against a peer median of -22.2%.
- Net debt amounts to 42.4% of total assets for TXG, versus a peer median of 17.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $2.32B | -2.7% | -14.4% | 19.2% | |
| Jul 2026 | $2.19B | +16.9% | -3.0% | 15.7% | |
| Jun 2026 | $1.49B | -10.6% | -9.7% | 22.4% | |
| Jun 2026 | $875.12M | +23.2% | -14.3% | 14.9% | |
| Jun 2026 | $686.7M | -33.8% | +1.6% | 6.7% | |
| Sep 2026 | -$64.48M | -125.8% | -55.4% | 2.4% | |
| Mar 2026 | -$236.28M | -98.0% | — | 37.0% | |
| Sep 2026 | -$439.01M | -860.1% | — | 39.1% | |
| Sep 2026 | -$450.4M | -67.4% | — | 42.4% | |
| Peer median (excluding TXG) | $780.91M | -22.2% | -12.0% | 17.5% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 587.45M | 219.75M | 359.28M | 344.07M | 473.97M |
| Short-term Investments | 0 | 210.24M | 29.41M | 49.34M | 49.44M |
| Net Receivables | 85.25M | 104.21M | 114.83M | 87.86M | 82.49M |
| Inventory | 59.97M | 81.63M | 73.71M | 83.11M | 56.34M |
| Other Current Assets | 1.03M | 19.21M | 18.79M | 20.02M | 22.21M |
| Total Current Assets | 747.59M | 635.04M | 596.02M | 584.39M | 684.45M |
| Property, Plant & Equipment (Net) | 230.41M | 359.21M | 344.93M | 309.94M | 287.16M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 25.4M | 22.86M | 16.62M | 15.67M | 62.33M |
| Long-term Investments | 7.6M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.32M | 7.37M | 3.06M | 4.13M | 2.91M |
| Total Non-current Assets | 271.24M | 393.95M | 369.12M | 334.25M | 356.91M |
| Total Assets | 1.02B | 1.03B | 965.14M | 918.64M | 1.04B |
| Account Payables | 17.35M | 21.6M | 15.74M | 12.91M | 12.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 10.99M |
| Tax Payables | 4.62M | 4.08M | 5.05M | 4.94M | 0 |
| Deferred Revenue | 5.34M | 7.87M | 13.15M | 20.66M | 23.9M |
| Other Current Liabilities | 40.91M | 29.74M | 33.96M | 41.84M | 63.33M |
| Total Current Liabilities | 110.36M | 130.96M | 127.16M | 117.63M | 153.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 73.38M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 3.17M | 8.81M | 12.51M | 10.5M |
| Other Non-current Liabilities | 14.05M | 2.98M | 4.28M | 5.03M | (65.67M) |
| Total Non-current Liabilities | 90.9M | 92.28M | 96.94M | 90.87M | 91.59M |
| Total Liabilities | 201.26M | 223.24M | 224.1M | 208.5M | 245.04M |
| Common Stock | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | (863.32M) | (1.03B) | (1.28B) | (1.47B) | (1.51B) |
| Accumulated OCI | 22K | (4.34M) | (429K) | (493K) | 225K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 817.57M | 805.74M | 741.04M | 710.13M | 796.33M |
| Total Debt | 81.98M | 95.18M | 95.37M | 82.61M | 157.74M |
| Net Debt | (505.47M) | (124.57M) | (263.91M) | (261.45M) | (316.23M) |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.